SMC OK's atazanavir, rabeprazole, valsartan/hydrochlorothiazide . . .

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.463, 2004-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Valsartan/Hydrochlorothiazide

By Langtry H.D. McClellan K.J.

Drugs, Vol. 57, Iss. 5, 1999-05 ,pp. : 751-755

Adis International

Access to resources Recommend Favorite

Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy

By Kondrack Robyn Mohiuddin Syed

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 9, 2009-09 ,pp. : 1125-1134

Informa Healthcare

Access to resources Recommend Favorite

Valsartan/Hydrochlorothiazide: A Viewpoint by A.D. Bremner

By Bremner A.D.

Drugs, Vol. 57, Iss. 5, 1999-05 ,pp. : 756-758

Adis International

Access to resources Recommend Favorite

Valsartan/Hydrochlorothiazide: A Review of its Use in the Management of Hypertension

By Wagstaff Antona J.

Drugs, Vol. 66, Iss. 14, 2006-01 ,pp. : 1881-1901

Adis International

Access to resources Recommend Favorite

Valsartan/hydrochlorothiazide: Pulmonary oedema in an elderly patient: case report

Reactions Weekly, Vol. 1, Iss. 1324, 2010-01 ,pp. : 34-35

Adis International

Access to resources Recommend Favorite